Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N03AXOrphan Medicine

Epidyolex(cannabidiol)

Lennox Gastaut Syndrome;Epilepsies, Myoclonic

Marketing Authorisation Holder: Jazz Pharmaceuticals Ireland Limited

EMA Authorisation: 19/09/2019

INN: cannabidiol

Indication

Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Epidyolex — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.